Gender Specific Association of RAS Gene Polymorphism with Essential Hypertension: A Case-Control Study

Table 3

Distribution of genotype frequencies of RAS gene polymorphisms in patients and control subjects.

SNPs	Genotype	Case % (𝑁=211)	Control % (𝑁=211)	OR	95% CI	𝑃 value
AGT M235T	MM	6.16	14.22	Ref
	MT	38.39	36.97	2.40	1.11–5.37	0.016
	TT	55.45	48.82	2.62	1.24–5.76	𝟎.𝟎𝟎𝟔^∗
Male	MM	8.26	12.31	Ref
	MT	39.45	36.92	1.59	0.59–4.52	0.320
	TT	52.29	50.77	1.54	0.58–4.25	0.340
Female	MM	3.92	17.28	Ref
	MT	37.25	37.04	4.43	1.21–20.09	0.011
	TT	58.82	45.68	5.68	1.60–25.10	𝟎.𝟎𝟎𝟐^∗
ACE I/D	II	18.96	24.17	Ref
	ID	41.71	44.08	1.21	0.71–2.07	0.467
	DD	39.34	31.75	1.58	0.90–2.76	0.087
Male	II	17.43	23.08	Ref
	ID	36.70	51.54	0.94	0.45–2.02	0.870
	DD	45.87	25.38	2.39	1.09–5.27	0.020
Female	II	20.59	25.93	Ref
	ID	47.06	32.10	1.85	0.80–4.28	0.117
	DD	32.35	41.98	0.97	0.42–2.25	0.940
ACE G2350A	GG	71.09	72.51	Ref
	GA	23.22	22.27	1.06	0.65–1.73	0.793
	AA	5.69	5.21	1.11	0.43–2.88	0.805
Male	GG	71.56	77.69	Ref
	GA	22.02	17.69	1.51	0.42–5.66	0.472
	AA	6.42	4.62	1.35	0.67–2.71	0.359
Female	GG	70.59	64.20	Ref
	GA	24.51	29.63	0.75	0.37–1.54	0.400
	AA	4.90	6.17	0.72	0.16–3.32	0.620
AGTR1 A1166C	AA	41.71	40.28	Ref
	AC	39.81	39.34	0.98	0.62–1.53	0.917
	CC	18.48	20.38	0.88	0.50–1.53	0.622
Male	AA	37.61	40.77	Ref
	AC	44.04	40.00	1.03	0.47–2.24	0.540
	CC	18.35	19.23	1.19	0.65–2.19	0.930
Female	AA	46.08	39.51	Ref
	AC	35.29	38.27	0.79	0.39–1.61	0.484
	CC	18.63	22.22	0.72	0.30–1.70	0.409

𝑁: sample size; OR: odds ratio; CI: confidence interval; Ref: reference; ^∗𝑃<0.05: statically significant.